RVMD Q3 2022 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$20B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+204.8% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$77M-2280.5% margin

Net Income

-$73M-2185.0% margin

EPS (Diluted)

$-0.87

QoQ Revenue Growth

-63.2%

Cash Flow

Operating Cash Flow

-$52M

Free Cash Flow

-$55M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$826M

Total Liabilities

$144M

Stockholders' Equity

$681M

Cash & Equivalents

$179M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$1M	+204.8%
Gross Profit	$3M	$1M	+204.8%
Operating Income	-$77M	-$53M	-44.0%
Net Income	-$73M	-$53M	-38.5%

Revenue Segments

Collaboration Revenue Member

$3M100%